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Review article

Hormonal contraception among electronic cigarette users and
cardiovascular risk: a systematic review☆,☆☆,★
Halley E.M. Riley a,⁎, Erin Berry-Bibee a , Lucinda J. England b , Denise J. Jamieson a ,
Polly A. Marchbanks a , Kathryn M. Curtis a
a

Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
b
Office on Smoking and Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
Received 6 October 2015; revised 26 October 2015; accepted 1 November 2015

Abstract
Background: Women who use combined hormonal contraceptives and cigarettes have an increased risk for cardiovascular (CV) events. We
reviewed the literature to determine whether women who use hormonal contraceptives (HC) and electronic cigarettes (e-cigarettes) also have
an increased risk.
Study Design: Systematic review.
Methods: We searched for articles reporting myocardial infarction (MI), stroke, venous thromboembolism, peripheral arterial disease or
changes to CV markers in women using e-cigarettes and HC. We also searched for indirect evidence, such as CV outcomes among e-cigarette
users in the general population and among HC users exposed to nicotine, propylene glycol or glycerol.
Results: No articles reported on outcomes among e-cigarette users using HC. Among the general population, 13 articles reported on heart
rate or blood pressure after e-cigarette use. These markers generally remained normal, even when significant changes were observed. In three
studies, changes were less pronounced after e-cigarette use than cigarette use. One MI was reported among 1012 people exposed to ecigarettes in these studies. One article on nicotine and HC exposure found both exposures to be significantly associated with acute changes to
heart rate, though mean heart rate remained normal. No articles on propylene glycol or glycerol and HC exposure were identified.
Conclusion: We identified no evidence on CV outcomes among e-cigarette users using HC. Limited data reporting mostly acute outcomes
suggested that CV events are rare among e-cigarette users in the general population and that e-cigarettes may affect heart rate and blood
pressure less than conventional cigarettes. There is a need for research assessing joint HC and e-cigarette exposure on clinical CV outcomes.
© 2016 Elsevier Inc. All rights reserved.
Keywords: Electronic cigarettes; Hormonal contraceptives; Nicotine; Propylene glycol; Glycerol; Cardiovascular disease

1. Introduction
Use of electronic nicotine delivery systems, especially
electronic cigarettes or e-cigarettes (ECs), is increasing in the
United States [1–3]. Among 2012–2013 National Adult
Tobacco Survey respondents, 14.1% reported ever use of
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ECs, and 4.2% reported using ECs every day, some days or
rarely. Among female respondents, 3.6% reported use every
day, some days or rarely [1]. ECs were also the most
commonly used tobacco product reported in a 2011–2014
nationally representative survey of US high school students,
with 13.4% reporting use in the past 30 days [4]. At the same
time, rates of current conventional cigarette use appear to be
decreasing among women of reproductive age (WRA). In a
2013 national survey, 15.4% of women aged 18–24 and
17.1% of women aged 25–44 years reported regular cigarette
use, down from 18.3% and 22.6%, respectively, in 2005 [5].
However, among EC users, simultaneous use of cigarettes
appears to be common [6]. Although ECs are often promoted
as safer alternatives to cigarettes, data on health effects
associated with their use are limited [7–9].
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ECs generally consist of a sensor, a microprocessor that is
activated when air is inhaled, a battery, a heating device or
aerosol generator and a storage unit containing e-liquid. Several
generations of EC devices exist, and products may be
rechargeable, reusable and modifiable by users [10]. During
use (often referred to as vaping), users activate devices' heating
components to create an inhaled aerosol [11,12]. Contents of the
e-liquid differ by brand and type but generally include nicotine,
glycerol and/or propylene glycol, flavoring and other additives.
One study analyzed EC aerosol for carcinogens and toxicants
and detected formaldehyde, acetaldehyde, acrolein, volatile
organic compounds, tobacco-specific nitrosamines and metals
(cadmium, nickel and lead). The presence of these toxicants was
found to be lower in ECs than in conventional cigarettes but
higher compared with nicotine inhaler mist [10,13]. E-liquid
nicotine levels also varied by brand and type, with many
containing 6–24-mg nicotine/mL e-liquid [14]. In some cases,
true nicotine content differed significantly from concentrations
indicated on product labels [15–17]. By comparison, conventional cigarettes contain about 10–15-mg nicotine/cigarette and
deliver about 1-mg nicotine for each cigarette smoked [14].
Evidence is mixed on whether ECs deliver nicotine at rates
comparable to conventional cigarettes, but several studies have
found ECs to increase users' blood and saliva nicotine and
cotinine levels [10].
For more than 50 years, evidence has accumulated on the
causal link between conventional cigarette smoking and
cardiovascular disease (CVD) through various mechanisms,
including atherogenesis, changes in endothelial function and
prothrombotic effects [18]. Women who smoke and use
combined hormonal contraceptives (CHC) are at an even higher
risk of CVD compared with women having only one of these
risk factors. CHCs contain both estrogen and a progestin and
include combined oral contraceptives (COCs), the combined
contraceptive vaginal ring and the combined transdermal
contraceptive patch. Observational studies and meta-analyses
have reported elevated risks of coronary heart disease,
myocardial infarction (MI), stroke, venous thromboembolism
(VTE) and peripheral arterial disease (PAD) among women
who smoke and use CHCs [18–29]. The mechanisms
underlying increased CVD risk in female smokers who use
CHCs are poorly understood but could include effects of
products of combustion, nicotine exposure or both.
Women who are exposed to nicotine through cigarette
smoking, EC use, nicotine replacement therapy (NRT) or
other sources and who become pregnant are at increased risk
for poor pregnancy outcomes [30–40]. Therefore, preventing unintended pregnancy in these women and delaying
pregnancy until cessation of tobacco to prevent nicotine
exposure is a key strategy for improving pregnancy and
perinatal outcomes. National evidence-based recommendations for contraceptive use generally recommend that
smokers should not use CHCs because of increased risk
for CVD [41,42], but no guidelines for EC use exist.
Although ECs do not produce the products of combustion
found in conventional cigarettes, there is concern among
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family planning providers as to whether EC users may be at
increased risk of CVD if they use CHCs.
The safety of hormonal contraceptive (HC) use among
women who use ECs is an important clinical question. In a 2012
survey of members of the American College of Obstetricians
and Gynecologists (n=252), 13.5% of respondents reported that
they believed ECs had no health effects, and 36.5% of
respondents (n=92) reported that they did not know the health
effects of EC use [43]. Given the increase in EC use in the
United States and the popularity of HC, especially CHCs, family
planning providers may increasingly see EC users who wish to
initiate or continue CHCs. The objective of this review is to
evaluate data regarding cardiovascular risks among EC users
who are exposed to HC.
2. Materials and methods
We conducted this systematic review according to
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses guidelines [44]. We searched for studies
that addressed one of four research questions.
Research question #1 (our primary research question)
was, “Are female e-cigarette users who use HC at
heightened risk for adverse cardiovascular outcomes
compared with female e-cigarette users who do not
HC?” While CHCs specifically have been associated with
increased risk for cardiovascular events among women
who smoke, to be comprehensive, we included all HC
methods in our search.
Because we anticipated that we would identify little
evidence for this question, we developed three additional
research questions to search for indirect evidence that
could help assess the risk for cardiovascular events
among HC users who use ECs.
Research question #2: Among the general population
(men and women), are EC users at increased risk of
adverse cardiovascular outcomes (clinical events or
changes to intermediary markers) compared with people
who do not use ECs (regardless of HC use status)?
Research question #3: Among women exposed to
nicotine (a common component of ECs) from any source
other than cigarettes including smokeless tobacco products and NRT, are those who use HC at increased risk of
adverse cardiovascular outcomes (clinical events or
changes to intermediary markers) compared with
women who do not use HC?
Research question #4: Among women exposed to inhaled
propylene glycol or glycerol (additional common components of ECs), are those who use HC at increased risk
of adverse cardiovascular outcomes (clinical events or
changes to intermediary markers) compared with women
who do not use HC?
We searched the PubMed and Cochrane Library databases from database inception through June 2015 for articles
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in any language that addressed our research questions.
Search strategies can be found in Appendix A. We did not
include case studies, case reports or conference proceedings.
For research question #2, we included studies of both women
and men, because evidence on EC use is limited and because
existing studies generally do not report results by sex. For
EC exposure, we included studies in which participants
primarily used nicotine-containing ECs. For contraceptives,
we included any HC method, including COCs, the combined
transdermal contraceptive patch, the combined hormonal
vaginal ring, combined injectable contraceptives, progestin-only pills, progestin-only implants, progestin-only injectables and levonorgestrel-releasing intrauterine devices. We
were primarily interested in the clinical outcomes of MI,
stroke, VTE and PAD but included studies that reported on
intermediary outcomes that might serve as proxy measures
for risk. For intermediary outcomes, we included changes in
blood pressure (BP), lipid levels [cholesterol, high-density
lipoprotein (HDL), low-density lipoprotein (LDL) and
triglycerides] and C-reactive protein levels, all measures of
cardiovascular risk [45,46], in addition to changes in heart
rate, as that is a widely reported cardiovascular marker.
Two authors (HR and KC) reviewed titles, abstracts or
full articles to identify studies that met inclusion criteria.
Evidence was summarized and assessed using standard data
abstraction forms [47]. We considered multiple methodological factors that could introduce bias, including whether a
standardized exposure was used in intervention trials,
whether an appropriate comparison group (a non-EC
comparison, single-group before-and-after comparison only
or no comparison group) was used, whether the study
measured outcomes over an acute or longer duration,
whether the outcome was validated biochemically or by
self-report only, whether there was adequate adjustment for
confounders and whether sample size, power and follow-up
rates were adequate. The quality of each individual study
was assessed using the United States Preventive Services
Task Force grading system [48]. Because of heterogeneity in
study design and measurement of outcomes, we did not
compute summary measures of association across studies.

3. Results
3.1. Research question #1
Our search for evidence on risk for CVD among women
using HC and ECs yielded no articles.
3.2. Research question #2
Our search for evidence on EC use and risk for adverse
cardiovascular events among men and women yielded 535
articles. Of these, 13 articles met inclusion criteria for this
review [49–61]. One article reported on the clinical
outcomes of interest (two cases of MI) [49]. Eleven articles
measured heart rate and BP after EC exposure [50–60]. In 5

of these articles, investigators followed participants for at
least 1 week [49,57–60], but in 7 articles, authors only
reported acute outcomes (changes over b 5 h of exposure)
[50–56]. One article reported on a cross-sectional survey in
which EC users reported on perceived changes to health after
switching from cigarettes to ECs [61]. Twelve articles
included data on both men and women together, with one
reporting on women alone [56].
3.2.1. Longitudinal studies
In the five articles that reported on cardiovascular outcomes
among EC users followed longitudinally [49,57–60] (Table 1),
follow-up periods ranged from 7 days to 1 year. One
double-blind randomized controlled trial (RCT) of fair quality
assigned 300 smokers (110 women) to one of three arms [58].
Investigators provided all users with the same EC model, but
each arm received cartridges with different nicotine content (a
12-week supply of 7.2-mg nicotine/mL, a 6-week supply of
7.2-mg nicotine/mL and a 6-week supply of 5.4-mg nicotine/
mL or a 12-week supply of 0.0-mg nicotine/mL). Participants
used ECs as they wished for up to 12 weeks, with study visits
every 2 weeks and additional visits at weeks 24 and 52 weeks.
The investigators made no restrictions on conventional cigarette
use. At each study visit, investigators measured heart rate and
BP and collected data on adverse events. No serious adverse
events were reported. The authors reported no statistically
significant changes in resting heart rate or BP from baseline to
the end of the study or between groups throughout the study but
reported no values for these outcomes.
Two poor quality case series (uncontrolled longitudinal
studies) and one fair quality randomized crossover study
provided current smokers with ECs and followed them for
7–14 days [57,59,60]. In the first report, investigators
provided 15 smokers (5 women) with ECs containing
0.0144-mg nicotine/0.8-mL e-liquid [57]. Participants were
instructed to use ECs rather than cigarettes for 2 weeks.
Investigators measured BP and heart rate at baseline and day
14 and reported no statistically significant changes to either
parameter, but no values were reported. The second case
series provided 29 smokers (10 women) with an EC
containing a 26-mg nicotine/mL e-liquid cartridge [59].
Participants used ECs for 20 min at the study site then used
them as they wished for 7–10 days with no restrictions on
conventional cigarette use. Participants returned after 7–10
days and used the ECs under observation (for two 10-puff
bouts). No serious adverse events were reported. During the
second observation session (after 7–10 days of exposure),
heart rate increased statistically significantly from a baseline
mean of 68 beats per minute (bpm) to 73.3 bpm at 10 min
after the first 10-puff bout and to 72.8 bpm at 10 min after the
second 10-puff bout. Even with these statistically significant
increases, mean heart rate remained well within normal range
for resting heart rate (60–100 bpm for adults) [62].
In the crossover study, 20 participants (9 women) were
randomized to receive ECs containing 18-mg nicotine/mL
e-liquid in either menthol or nonmenthol tobacco flavor.

Table 1
Longitudinal studies of EC use.
Study
design

Population
(including WRA)

Exposure(s)

Cardiovascular
outcome(s)

Results

Strengths

Caponnetto, 2013 [58],
Italy. Lega Italiana
AntiFumo/University
of Catania, Italy

Doubleblind
RCT
(3 arms)

300 smokers (110 women)
who had smoked ≥10
cigarettes/day for ≥5 years.
Average age = 44 years
(SD +/−12.5 years).
Excluded: symptomatic
CVD, respiratory disease,
psychotropic drug use,
current or past alcohol abuse,
use of smokeless tobacco,
or NRT, pregnancy/lactation.

Three products, participants
randomized to exposure
condition.
Products:
All participants used the same
EC model, with different
cartridges provided.
1) 7.2-mg nicotine/mL
cartridges (12-week supply).
2) 7.2-mg nicotine/mL
cartridges (6-week supply) +
5.4-mg nicotine cartridges
(6-week supply).
3) 0-mg nicotine/mL
cartridge (12-week supply).
Product administration:
Participants used ECs provided
ad lib. Participants could return
to study site every 2 weeks for
12 weeks (seven study visits)
for additional study supplies.

Resting heart rate,
measured at each
study visit (baseline,
weeks 2, 4, 6, 8,
10, 12, 24, 52).
BP, measured at
each study visit
(baseline, weeks
2, 4, 6, 8, 10,
12, 24, 52).
Adverse events
reported.

No statistically
significant changes
in mean resting
heart rate or systolic/
diastolic BP from
baseline to end of
the study
observed overall.
No statistically
significant differences
in heart rate or systolic/
diastolic BP reported
between 3 study groups
throughout study.
No point estimates
reported.
No serious adverse
events reported.

van Staden, 2013 [57],
South Africa. ECs
used in study
provided by Twisp
EC Company

Case
series

15 smokers (5 women)
who had smoked 10–30
cigarettes/day; had been
smoking for a median
of 17 years.
Age range: 23–46 years
(median, 38 years).
Excluded: individuals with
known history of
heart disease.

Product: EC containing
0.0144-mg nicotine/
0.8-mL e-liquid.
Product administration:
Participants used EC instead
of cigarettes (as they would
use cigarettes) for 2 weeks.

BP and heart rate,
at baseline and at
2 weeks.

No statistically
significant changes
in BP or heart rate
from baseline
to day 14.

No point estimates
reported for changes
in resting heart rate
or BP.
Study powered on
quit rate, not on
changes in BP or
heart rate.
High loss to
follow-up (35%–
45% over 52 weeks)
and differential by
groups (0-mg nicotine
group lost more than
either nicotine group).
Results not reported
by sex.
No standardized study
exposure (participants
used ECs ad lib;
participants were
allowed to use
cigarettes throughout
the study).
No nonuser
Controlled for
effects of smoking comparison group.
Small sample size.
by enrolling
No standardized
only smokers.
dose (ad lib EC use).
Participants used
No clear description
ECs in “real life”
of sample frame/
setting. ~87% of
recruitment strategy.
participants
Authors were unable
followed for
to determine
2 weeks.
participants' cigarette
exposure status.
Results not reported
by sex.
No exclusions for
chronic health
conditions other than
chronic lung disease.
Powered on changes
in arterial COHb
Randomization
and blinding
procedures
described.
Controlled for
effects of smoking
by enrolling
only smokers.
Two different
nicotine content
ECs compared
with nonnicotine
exposed control
group. Long-term
follow-up (1 year).
Excluded
symptomatic CVD
(unclear whether
hypertensive
individuals
were excluded)

Weaknesses

Grading of
quality⁎
I; Fair

II-3;
Poor
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Author, year, location,
sources of support
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Table 1 (continued)
Author, year, location,
sources of support

Study
design

Population
(including WRA)

Case
series

29 smokers (10 women)
who had smoked ≤10
cigarettes/day for past year.
Age range: 18–63 years
(mean, 43 years).
45% of participants had never
used an EC, 48% had used
b10 ECs in lifetime,
7% had used N10 ECs.
Excluded: pregnant or
breastfeeding women,
individuals reporting current
drug abuse, use of prescription
psychiatric or opioid medications,
use of EC within 14 days
prior to study; use of nicotine
replacement products within
30 days prior to study;
consumption of alcohol
within 24 h prior to Session 3.

Oncken, 2015 [60],
US. Funded by
internal funding
from University
of Connecticut
Health Center.

Randomized 20 smokers (9 women) who
crossover
smoked ≥ 10 cigarettes/day
study
and agreed to switch to ECs
for 2 weeks.
Excluded: pregnant women,
individuals with history of
MI or stroke, uncontrolled
hypertension, insulin
dependent diabetes, COPD,
current asthma, or allergy
to propylene glycol.

Cardiovascular
outcome(s)

Results

Strengths

Product:
EC with 26-mg
nicotine/mL
e-liquid cartridge.
Product administration:
1) Participants used ECs
ad lib for 20 min in clinic.
2) Participants were given
ECs and instructed to use
them as often as they liked
for 7–10 days, maintaining
EC use diary.
3. Participants used ECs
for 2 series of 10-puff
bouts with 30 s
interpuff interval.

Heart rate measured
at 20-s intervals
beginning 5 min
before the first puff
of each visit and
continuing until
35 min after each
set of puffs.

During Session 3,
heart rate increased
statistically significantly
from a baseline mean
of 68 bpm to 73.3 bpm
at 10 min after first
10-puff bout and to
72.8 bpm at 10 min
after second 10-puff
bout (pb0.004).

Controlled for
effects
of smoking by
enrolling
only smokers.
Participants
used ECs in
“real life” setting.
~88% follow up
over 3 weeks.

Products:
18-mg/mL nicotine e-liquid
cartridge flavored with a)
menthol-tobacco flavoring
and menthol, b) tobacco
flavoring only.
Product Administration:
Participants used each EC
for 7–10 days and then
were monitored using EC
in laboratory for 5 min
ad lib (heart rate and BP
measured during
laboratory session).
Participants then repeated
procedures with
alternative flavor.

Heart rate and BP
measured 5 min
before and 5, 10,
15, 29 and 30 min
after 5 min
of ad lib EC use.

No significant increases
in systolic or diastolic
BP or heart rate were
observed during
laboratory sessions.
No main effects for
sex were observed
for these parameters.
Mean heart rate
(collapsed over sessions)
changed from ~67.5 bpm
at baseline to 68.5 bpm
after 5 min of EC use,
then remained betweeen
66 and 68 bpm for
remainder
of the sessions.
Systolic bloood pressure
remained between

Analyzed heart
rate and BP
by sex.
Standardized
exposure during
laboratory session.

Weaknesses
levels (not BP or
heart rate).
No nonuser
control group.
Nonstandardized
EC dose.
Participants were
allowed to use
cigarettes throughout
the study.
Authors only
measured acute
outcomes after brief
exposure; no
long-term follow-up.
Results not reported
by sex.
No sample size or
power calculations
provided.
Participants were
in “general good
health”; unclear
if this included
those with high
BP or other risk
factors for CVD.
Nonstandardized
exposure during
7–10 days of use.
No non-EC
comparison group.
Small sample size.
Randomization
procedures not
described.
Study powered
on changes to
nicotine levels,
not on changes in
BP or heart rate.
66% follow-up rate.

Grading of
quality⁎

II-3,
Poor

I,
Fair
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Nides, 2014 [59],
US. NJOY, Inc.
(EC company)

Exposure(s)

Manzoli [49], 2015,
Italy. No source of
funding reported.

Products:
Participants provided
their own ECs and
conventional cigarettes.
Reported nicotine
content of ECs used:
EC group:
No nicotine, 12.8%
3–8 mg: 23.5%
9 mg: 40.7%
10–24 mg: 23.0%.
Dual users:
No nicotine, 5.6%
3–8 mg: 19.1%
9 mg: 34%
10–24 mg: 41.4%.
N 90% of all EC
users reporting
use of nicotinecontaining ECs.
Product administration:
Participants used
products on
their own for
12 months and
recorded smoking
behavior through
questionnaire.

Possibly related
serious adverse
events reported
at 12 months.

Included non-EC
comparison
group 12month follow-up.
Clear description
of sample frame/
recruitment
strategies.

Nonstandardized
II-2,
exposure (participants Poor
used cigarettes or
ECs under “real life”
conditions) and
self-reported use.
Nonstandardize
product: individuals
could used their
own ECs.
Nonvalidated
outcomes (25%
of participants
reporting tobacco
cigarette abstinence
tested for CO levels;
results nonvalidated
for others).
Results not reported
by sex.
No power calculations
reported.
~ 30% of sample lost
to follow up between
baseline and
12 months (no
significant differences
in loss to follow up
between groups).

H.E.M. Riley et al. / Contraception 93 (2016) 190–208

Prospective 12-month follow-up data
cohort study provided for: - 236 EC
users (88 women): had
used any type of EC
≥50 puffs/week for
≥6 months prior to
baseline. - 491
conventional cigarettes
smokers (252 women):
smoked ≥1 cigarette/
day for ≥6 months
prior to baseline. - 232
dual users (83 women):
had used both
conventional cigarettes
and ECs in the same week
for the past 6 months
Excluded: age b 30
or N 75 years, pregnancy/
lactation, illicit drug use,
major depression, severe
allergies, angina and past
major smokingrelated disease.

120 125 mmHg from
baseline through 30 min
after 5 min of use.
Diastolic BP remained
between 70 and 80 mmHg
from baseline through
30 min after 5 min of use.
One acute MI reported in
group of dual users who
quit tobacco cigarettes and
continued with ECs only
at 12 months (n=24).
One acute MI reported in
group of smokers who
continued with tobacco
cigarettes only at
12 months (n= 381).
Age, sex and level
of nicotine intake not
reported for either
individual
experiencing MI.

COHb: Carboxyhemoglobin; COPD, chronic obstructive pulmonary disease; SD, standard deviation; WRA, women of reproductive age.
⁎ US Preventive Services Task Force (USPSTF) grading criteria used to assess study quality [48].
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Participants used ECs for 7–10 days in lieu of conventional
cigarettes, returned to the laboratory for a monitoring session
(5 min of EC use with heart rate and BP recorded) and then
repeated the procedure with the alternative flavor [60]. No
significant increases to heart rate or BP were recorded in the 30
min of observation following either laboratory session, with
mean heart rate ranging from ~66 to 69 bpm, mean systolic BP
ranging from 120 to 125 mmHg and mean diastolic BP
remaining ~ 75 mmHg throughout the observation periods.
One prospective cohort study (poor quality) recruited
1355 Italian adults who reported either conventional
cigarette use (at least one cigarette per day for 6 months
prior to recruitment, n= 693), EC use (at least 50 puffs per
week for 6 months prior to recruitment, n= 343) or dual use
(use of both products within the same week for 6 months
prior to recruitment, n= 319) [49]. Investigators planned to
follow participants for 60 months but reported preliminary
results at 12 months for 491 conventional cigarette users
(252 women), 236 EC users (88 women) and 232 dual users
(83 women). Participants provided their own cigarettes and
ECs, with e-liquid nicotine levels ranging from 0- to 24-mg
nicotine/mL (with N 90% of all EC users reporting use of
nicotine-containing ECs). Two acute MIs reported in year 1
of the study were classified as adverse events possibly
related to the study exposure. One occurred among the group
of dual users who had switched to EC use only (n= 24), and
the other was reported among the group of conventional
cigarette smokers who continued with cigarette use only (n=
381). Authors did not report age, sex or level of EC or
cigarette use for individuals experiencing MIs.
3.2.2. Studies of acute exposures
We identified seven studies in which investigators observed
individuals using ECs in laboratory settings for short time
periods (≤ 5 h of observation per session) [50–56] (Table 2).
Participants attended one [50,54] to six [53] sessions. Each of
these studies reported only acute results (e.g., changes to heart
rate or BP after short periods of EC use). None reported on
clinical cardiovascular outcomes of interest.
One fair quality nonrandomized trial compared 40 current
EC users (all former smokers) with 36 current smokers (6
women total) [50]. There were no statistically significant
differences in baseline diastolic or systolic BP, heart rate,
total cholesterol, LDL cholesterol, HDL cholesterol or
triglycerides between current smokers and current EC
users. Participants in the EC group used an EC containing
11-mg nicotine/mL e-liquid for 7 min ad lib, while
participants in the smoker group smoked one cigarette
under observation. In the EC group, no statistically
significant changes to mean heart rate (from 67.1±10.3 to
67.5±10.6 bpm) or systolic BP (from 123.9±8.6 to 124.6±9.9
mmHg) were observed between baseline and after exposure,
but a statistically significant change in mean diastolic BP
was observed after EC use (from 75.6±6.2 to 78.5±5.9
mmHg, pb0.001). In the smoker group, investigators
reported statistically significant increases for each of these

parameters after cigarette exposure. Mean heart rate
increased from 67.5±10.3 to 73.5±6.8 bpm (pb0.001),
mean systolic BP increased from 123±8.6 to 129.6 mmHg
(pb0.001) and mean diastolic BP increased from 75.8±5.6 to
80.2±5.8 mmHg (pb0.001). Between-group changes were
significantly different for mean heart rate and systolic BP
(pb0.001 for both parameters). In both groups, diastolic BP
and heart rate remained within normal ranges [63]. Mean
systolic BP was in the prehypertensive range [63] at baseline
and remained in this range.
Two randomized crossover studies exposed individuals to
four [52] or six products [53], with participants randomized
to exposure order. In the first study (poor quality), 32
smokers (13 women) used four products (an EC with a
cartridge containing 18-mg nicotine/mL e-liquid, an EC with
a cartridge containing 16-mg nicotine/mL e-liquid, chosen
brand of conventional cigarette and an unlit cigarette) for 10
puffs, then repeated the procedure after an hour with the
same product, with heart rate measured every 20 s [52]. Four
sessions were completed (one session per product) with a
≥ 48-h washout period between sessions. The authors
reported no statistically significant changes in heart rate
after exposure to either EC or the unlit cigarette. Mean heart
rate increased significantly between baseline and 5 min after
exposure to conventional cigarettes (from 65.7 bpm to 80.3
bpm) compared with the unlit cigarette or either EC (no
p-value reported). In the second crossover study (fair
quality), 23 smokers (12 women) took 50 puffs of six
products (five ECs containing from 1.6% to 2.4% nicotine
and varying levels of propylene glycol and glycerin and a
conventional cigarette), then used each product ad lib for 1
h. Participants completed six sessions (one per product) with
a ≥ 24-h washout period between sessions [53]. The authors
observed statistically significant increases to mean diastolic
BP after use of all products compared with baseline (with
baseline means ranging from 70±8.9 to 73±8.6 mmHg over
the six sessions and postexposure means ranging from 76±
9.3 to 78±10.1 mmHg) and observed a statistically
significant increase to mean systolic BP after use of the
EC containing 1.6% nicotine and ~ 75% glycerin (from 118
mmHg to 124 mmHg, p=0.02) and the conventional cigarette
(from 120 mmHg to 126 mmHg, p=0.04). For all other
products, authors observed nonstatistically significant (NS)
increases to systolic BP. The authors noted statistically
significant increases to mean heart rate after use of an EC
containing 2.4% nicotine, ~ 50% glycerin and ~ 20%
propylene glycol (from 71 to 75 bpm, p=0.008), an EC
containing 2.4% nicotine and ~ 75% glycerin (from 70 to 74
bpm, p=0.002) and the conventional cigarette (from 70 to 74
bpm, p=0.001).
We identified two fair quality nonrandomized crossover
studies in which investigators examined cardiovascular
markers after conventional cigarette versus EC exposure.
In the first study, 42 individuals (21 women) participated in
two sessions separated by a 7-day washout period [55]. In the
first session, individuals smoked a conventional cigarette for

Table 2
Acute studies of EC use.

Farsalinos, 2014a
[50], Greece.
No specific grant
funding listed.
Authors have
performed other
studies funded by
EC companies.

Vansickel, 2010
[52], US.
NIH (NCI)

Population
(including WRA)

Exposure(s)

Cardiovascular
outcome(s)

Nonrandomized 76 participants:
trial; 2 arms
- 36 smokers (3 women),
smoking for ≥
15 cigarettes/day
for ≥5 years
- 40 current EC users,
all former smokers
(3 women) using ECs
for ≥1 month, using
9–12 mg/mL
nicotine e-liquid
Mean age: 36 years.
Excluded individuals
with major risk
factors for CVD,
including hypertension
and with abnormal
echocardiograph results.

Products:
1) EC containing
11-mg nicotine/mL
e-liquid (former
smoker exposure).
2) Conventional
cigarette
(smoker exposure).
Product Administration:
1) Participants in
EC group used EC
ad lib for 7 min).
2) Participants in
smoking group
smoked one cigarette.

Heart rate and BP
at baseline and after
exposure.

Randomized
crossover study

Four sessions with
N48-h washout
period between sessions.

32 smokers (13 women)
who smoked ≥
15 cigarettes/day

Results

EC: No statistically
significant changes
to mean heart rate
(from 67.1±10.3 to
67.5±10.6 bpm) after
EC administration
compared with baseline.
No statistically
significant changes to
mean systolic BP
(from 123.0±8.6 to
124.6±9.9 mmHg)
after EC administration
compared with baseline.
Statistically significant
increase in diastolic BP
after EC administration
(from 75.6±6.2 to
78.5±5.9 mmHg,
pb0.001) compared
with baseline.
Cigarette:
Statistically significant
increases in heart rate
(67.5±7.9 to 73.5±
6.8 bpm, pb0.001),
systolic BP (123±9.8
to 129.6±9.2 mmHg,
pb0.001), and diastolic
BP (from 75.8 ±5.6 to
80.2±5.8 mmHg,
pb0.001) after cigarette
exposure, compared
with baseline.
Changes to heart rate
and systolic BP were
significantly different
between groups
(pb0.001), but not
for diastolic BP
(p=0.079).
Heart rate, measured EC (18-mg and
every 20 s during the 16-mg nicotine) and
study sessions,
unlit cigarette groups:

Strengths

Weaknesses

Grading
of
quality⁎

Standardized dose.
Included non-EC
comparison group.
Excluded those
with risk factors
for CVD and family
history of CAD
and with abnormal
results on
echocardiograph
studies.

N 90% of the
study population
was male.
Results not
reported by sex.
Only short-term,
acute effects
measured.
Small sample size.
No sample size
or power
calculations
provided.

II-1,
Fair

All participants
were new EC users.
Controlled for

Authors only
measured acute
outcomes after

I,
Poor

(continued on next page)
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Author, year, location,
sources of support
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Table 2 (continued)
Author, year, location,
sources of support

Randomized,
partially
single-blinded
crossover study
(6 sessions)

Population
(including WRA)

Exposure(s)

Age range: 18–55 years
(mean: 33.6 years)
Excluded individuals
with self-report of
chronic health condition,
including high BP;
excluded pregnant or
breastfeeding women
and those who reported
previous EC use.

averaged over 5 min
Products:
before and after
1) Chosen brand cigarette.
2) Unlit own brand cigarette. product exposure.
3) EC with 18-mg
nicotine/mL
e-liquid cartridge.
4) EC with 16-mg
nicotine/mL
e-liquid cartridge.
Product administration:
Participants took
10 puffs w/30-s interpuff
interval with each product.
Product readministered
after 60 min.

23 smokers
(≥10 cigarettes/day
for at least 1 year);
12 women.
Age range: 23–58 years
(mean: 39 years).
Excluded those with
chronic mental or
physical health
condition; pregnancy
or breastfeeding;
elevated systolic or
diastolic BP or heart
rate; use of other
tobacco or nicotinecontaining products
and certain medications
(including prescription
smoking cessation drugs).

Cardiovascular
outcome(s)

Results

No statistically significant
changes in heart rate
observed for either 18-mg
nicotine/mL EC, 16-mg
nicotine/mL EC or sham
after exposure compared
with baseline (mean
heart rate between 60
and 70 bpm at all
time points).
Cigarette:
Statistically significant
increase in mean heart
rate from mean 65.7 bpm
at baseline to peak of
80.3 bpm 5 min after
cigarette exposure.
Increase after smoking
conventional cigarette
was statistically
significantly higher than
both sham and both EC
doses (pN0.001).
Six exposures sessions
Systolic BP, diastolic Heart rate:
with ≥24 h between
BP and heart rate
Statistically significant
sessions.
measured 30 min
increase in heart rate
Products:
before exposure and compared with baseline
1) 2.4% nicotine,
20 min after each
for Products 2, 3 and 6.
~75% glycerin EC.
exposure session.
Product 2: 71±8.95 to
2) 2.4% nicotine,
75±8.63 bpm, p=0.008
~50% glycerin,
Product 3: 70±7 to 74±
~20% propylene glycol EC.
7 bpm, p=0.002Product
3) 2.4% nicotine,
6: 70±5.9 to 74±8.6 bpm,
~75% glycerin menthol EC.
p=0.001.
4) 1.6% nicotine,
No statistically significant
~75% glycerin EC.
differences in change to
5) 1.6% nicotine,
heart rate between products.
~50% glycerin,
Authors observed
~20% propylene glycol EC.
correlation between users'
6) Cigarette.
nicotine plasma level and
increased heart rate.
Product administration:
BP:
EC sessions: 50 puffs
Statistically significant
(5-s long puffs with
increase in diastolic BP
30-s interpuff intervals);
after use of all products
30 min later, participants

Strengths

Weaknesses

effects of smoking
by only recruiting
smokers.
Standardized EC
exposure.
Non-EC
comparison
conditions.
Authors compared
two ECs with
different nicotine
contents.
Excluded participants
with health conditions.

brief exposure;
no long-term
follow-up.
Did not report
results for subset
of women
No sample size
or power
calculations
provided.
No clear
description of
sample frame/
recruitment
strategy.

Standardized dose.
Controlled for effects
of smoking by only
recruiting smokers.
Non-EC comparison
condition; authors
compared ECs with
different nicotine
contents.
Excluded participants
with health conditions
(including elevated
BP or heart rate).

Short-term,
acute effects only.
No sample
size or power
calculations
provided.
No clear
description of
sample frame/
recruitment
strategy.
Results not
reported by sex.

Grading
of
quality⁎

1;
Fair

H.E.M. Riley et al. / Contraception 93 (2016) 190–208

Yan, 2014 [53],
US. Blu ECs
(LOEC, Inc)

Study design

used EC ad lib for 1 h.
Cigarette session:
Smoked one cigarette
(normal puffs with
30-s interpuff intervals);
30 min later, participants
smoked cigarettes as
desired for 1 h.

Nonrandomized 42 smokers (21 women)
crossover study who smoked ≥
5 cigarettes/day, had
been smokers for ≥
1 year and had not
used ECs before
study initiation.
Each participant
participated in 2 sessions
with a 7-day washout
period between sessions.
Age range: 18–62 years
(mean age: 24.88 years old)
Excluded individuals
with allergies, respiratory

Two products; each
participant was
exposed to each product.
Participants participated
in two sessions with
1 week washout period
between sessions.
Products:
1) EC containing
14 mg/mL nicotine.
2) Conventional cigarette.
Product administration:
Participants used each
product for 5 min
(smoked one cigarette

H.E.M. Riley et al. / Contraception 93 (2016) 190–208

Czogala, 2012
[55], Poland.
Ministry of
Science and
Higher
Education
of Poland.

compared with baseline.
Product 1: 71±9.5 to
78±10 mmHg, p=6.77 E-05.
Product 2: 70±10 to
77±9.8 mmHg, p=4.83 E-05.
Product 3: 73±8.6 to
76.1 mmHg, p=0.048.
Product 4: 70±9 to
77±8 mmHg, p=0.1.9 E-08.
Product 5:72±7 to
76±9 mmHg, p=0.00017.
Product 6: 71±9.5 to
78±9.5 mmHg, p=0.00014.
Conventional cigarette
(Product 6) resulted in
significantly higher
change to diastolic BP
than product 3. No other
statistically significant
changes in diastolic
BP between products.
Statistically significant
increase in systolic BP
after use of Products 4
and 6 compared
with baseline.
Product 4: 118±10 to
124±12.5 mmHg, p=0.02.
Product 6: 120±12.6 to
123±12.96 mmHg, p=0.04.
No statistically significant
differences in change
to systolic BP between
products.
Heart rate, measured EC:
at baseline and 5 min No statistically significant
changes in heart rate,
after exposure.
Systolic and diastolic systolic BP or diastolic
BP after using an EC
BP, measured at
compared with baseline.
baseline and 5 min
No statistically significant
after exposure.
changes found when
results stratified by sex
(for systolic BP).
Cigarette:
Statistically significant
increase in heart rate
(from 78.50±11.96 to
90.90±15.40 mmHg,

Results (changes
to systolic BP)
reported by sex.
Non-EC comparison
condition.
Recruited only
smokers.
Excluded those
with chronic
medical conditions.

Authors only
measured acute
outcomes;
no long-term
follow-up.
No sample size
or power
calculations
provided.
No clear
description of
sample frame/
recruitment
strategy.
Authors did

II-1;
Fair

199

(continued on next page)

200

Table 2 (continued)
Author, year, location,
sources of support

Study design

Population
(including WRA)

Exposure(s)

and cardiovascular
conditions, arterial
hypertension, cancer
and pregnant women.
Excluded people who
had used ECs before study.

and used one EC).

Nonrandomized 15 healthy female
within subject
smokers (smoking ≥
crossover study 5 cigarettes/day for ≥
(2 sessions)
2 years) aged 19–25
years who also reported
using ECs ≥10 times.
Excluded: Individuals
aged b 18 years; individuals
with hypertension, other
circulatory system diseases,
cancer, hypercholesterolemia,
diabetes or pregnancy/
lactation, use of estrogen,
progestin or other hormones,
heart medications, NRT or
general health programs,
(e.g., chronic bronchitis
and asthma).

Vansickel, 2012
[51], US. NIH
(NCI/NIDA).

Interrupted
time series
(same exposure
repeated 5 times

20 smokers (9 women)
who smoked ≥15 cigarettes/
Day.
Age range: 18–55 years

Exposure:
Session 1: Participants
smoked one conventional
cigarette (10–12 puffs)
using filtered, slim
cigarette with nicotine
content: 0.7 mg.
Session 2: Participants
took 15 puffs with
same model EC
containing 24-mg
nicotine/mL e-liquid.

Changes to BP and
heart rate, measured
before and 10 min
after exposure.

Product:
EC containing 18-mg
nicotine/mL e-liquid.
Product administration:

Heart rate, measured
every 20 s, averaged
over 5 min.
BP, measured

Results

p=0.000) after smoking
cigarette compared
with baseline.
No statistically significant
increase to systolic BP
after smoking cigarette
compared with baseline.
Statistically significant
increases to diastolic BP
(from 78.79±11.00 to
84.14±10.44 mmHg,
p=0.02) after smoking
cigarette compared
with baseline.
No statistically significant
changes to heart rate or
BP were recorded after
conventional cigarette or
EC exposure.
Heart rate:
Increased from ~78 bpm
to ~80 bpm after EC
exposure (NS).
Increased from ~78 bpm
to ~86 bpm after
conventional cigarette
exposure (NS).
Systolic BP: Increased
from ~120 mmHg
to ~122 mmHg after
e- cigarette exposure (NS).
Increased from ~116 mmHg
to ~118 mmHg after
conventional cigarette
exposure (NS).
Diastolic BP: Remained at
~73 mmHg from baseline
to after EC exposure (NS).
Increased from ~74 mmHg
to ~76 mmHg after EC
exposure (NS).
Heart rate:
Statistically significant
increase in mean heart
rate from preadministration

Strengths

Weaknesses

Grading
of
quality⁎

not specify
whether EC
exposure was
consistent among
participants
(e.g., all
participants took
the same
number of puffs).

II–I, Fair

Standardized exposure.
Controlled for sex and
age by only including
WRA.
Controlled for smoking
status by recruiting
only smokers with
some EC experience.

Authors only
measured acute
outcomes;
no long-term
follow-up.
Small sample
size.
No sample size
or power
calculations
provided.
No nonuser
comparison group.

Standardized
EC exposure.
Controlled for
effects of

No nonuse
II-3,
comparison
Fair
group or condition.
Authors only

H.E.M. Riley et al. / Contraception 93 (2016) 190–208

Szoltysek-Boldys
[56], 2014,
Poland. Funded
by Chic
Group LTD
(manufacturer
of ECs in Poland)
and internal
funding from the
Institute of
Occupational
and Environmental
Health, Poland
and Medical
University of
Silesia, Poland.

Cardiovascular
outcome(s)

Participants took
10 puffs with 30-s
interpuff interval,
repeated 5 times at
30-min intervals.

Case series

8 EC users (3 women)
who had been using
ECs ≥ 3 months, using
≥2–3 mL of nicotine
solution or 2 cartridges/day;
smoked ≤5 cigarettes/day.
Age range: 18–55 years
(mean age: 33.5 years).
Excluded those with
self-report of chronic
health condition,
including high BP.

Heart rate,
Products: Participants
measured
provided their own ECs.
every 20 s.
One participant used
9-mg/mL nicotine solution;
Six participants used
18-mg/mL nicotine solution;
one participant used
24-mg/mL nicotine solution.
Product administration:
Participants took
10 puffs with a 30-s
interpuff interval.
Participants then used
ECs for 60 min ad lib
(number of puffs ranged
from 4–76).

19,411 current, former
or never smokers
(4900 women) aged
31–47 years
(mean: 39 years).

Exposure: Self-reported
EC use.
Participants reported on:
duration of use;
EC use patterns
(daily, occasionally,
not anymore); EC device
type most often used;
EC liquid use; EC daily

Farsalinos, 2014b
Cross-sectional
[61], Greece.
Web-based
E-Cigarette
survey
Research Advocates
Group
(www.ecigaretteresearch.com),
EC user group.

every 5 min.

Self-reported
changes to
preexisting
disease
conditions
(including
hypertension
and CAD)
after initiating

average of 67.5 bpm to
75 bpm observed within
5 min of first 10-puff bout.
Heart rate remained
statistically significantly
elevated compared with
baseline for first two
10-puff bouts only.
BP:
No statistically
significant changes
in systolic or
diastolic BP were
observed after
EC administration
compared with
baseline.
Mean heart rate increased
statistically significantly
from 73.2 bpm at baseline
to mean of 78 bpm
within 5 min of first puff.
Heart rate remained
elevated during remainder
of session.

Hypertension: 2365
participants (390
smokers, 1975 former
smokers) reported
hypertension prior to
EC initiation.
Of these, 19 (0.8%,
6 smokers and
13 former smokers)

smoking by only
recruiting
smokers.
Excluded those
with chronic
medical conditions.

measured acute
outcomes;
no long-term
follow-up.
Did not report
results for
subset of women
No sample size
or power
calculations
provided.
No clear
description of
sample frame/
recruitment
strategy.
BP values
not reported.
Nonstandardized
All participants were
EC dose.
experienced with EC
No nonuse
use and used own,
comparison
chosen devices
group or condition.
(real-world exposure).
No clear
Excluded current
description of
smokers.
sample frame/
Excluded participants
recruitment
with health conditions.
strategy.
Authors only
measured acute
outcomes; no
long-term
follow-up.
Did not report
results for subset
of women.
No sample size
or power
calculations
provided.
Global sample.
No information
Large sample size.
on sampling
Multivariate analysis
frame or how
included adjustment
participants
for confounders,
were recruited.
including demographics Self-reported
and amount of current
outcomes with
smoking and/or EC use. no validation.
Changes to

II-3;
Poor

H.E.M. Riley et al. / Contraception 93 (2016) 190–208

Vansickel, 2013
[54], US. NIH
(NCI/NIDA).

to single group) (mean age: 33.2).
Excluded individuals with
self-report of chronic health
condition, including high
BP, women who were
pregnant, breastfeeding,
or in active menopause
and current EC users.

II-3;
Poor
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Table 2 (continued)
Author, year, location,
sources of support

Study design

Population
(including WRA)

Cardiovascular
outcome(s)

Results

consumptions; current
nicotine levels in EC;
nicotine levels used
at initiation of EC use.

EC use.

reported condition
worsening after
EC initiation, 944
(39.9%, 194
smokers and 750 former
smokers) reported that
their condition remained
stable, and 1149 (49.9%,
139 smokers and
1040 former smokers)
reported improvement.
CAD: 318 participants
(68 smokers and
250 former smokers)
reported CAD prior to
EC initiation.
Of these, 7 (4 smokers
and 3 former smokers)
reported condition
worsening, 116 (30
smokers and 86 former
smokers) reported that
their condition remained
stable, and 171 (24
smokers and 147 former
smokers) reported
improvement.
In multivariate analysis,
odds of reporting
improvements were
1.96 times higher for
former smokers than
smokers (pb0.001). for
hypertension, and 2.02
times higher for former
smokers than smokers
(p=0.048) for CAD.
Among never smokers
using ECs, 18%
reported any condition
(7 options), with
81.3% reporting that
conditions remained
stable.

NCI, National Cancer Institute; NIDA, National Institute on Drug Abuse; NIH, National Institutes of Health; WRA, women of reproductive age.
⁎ USPSTF grading criteria used to assess study quality [48].

Strengths

Weaknesses

Grading
of
quality⁎

disease conditions
not reported by
disease for never
smokers.
Results not
reported by sex.
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Exposure(s)
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5 min, and in the second, the same individuals used one EC for 5
min. BP and heart rate were measured before and directly after
each exposure. The authors reported results by sex for systolic BP
only. No changes to systolic BP were observed among females
after EC use (~119 mmHG at baseline with no increase after
exposure), but they observed a NS increase in systolic BP among
females after conventional cigarette exposure (from ~120
mmHG to ~125 mmHG, pN0.05). Among men and women
combined, mean diastolic BP increased statistically significantly
after conventional cigarette use (from 78.79 mmHg to 84.14
mmHg, p=0.02) but not after EC use (from 76.71 mmHg to 78.60
mmHG, no p-value reported). Heart rate increased statistically
significantly after conventional cigarette use (from 78.5 bpm to
90.9 bpm, p-value reported as 0.000) and nonsignificantly after
EC exposure (77.93 bpm to 79.36 bpm, no p-value reported). The
change in heart rate after conventional cigarette use was
significantly higher than the change after EC use. In the second
nonrandomized crossover study, authors recruited healthy female
smokers (n=15) to participate in two sessions, separated by at
least 11 days [56]. In the first session, individuals smoked one
cigarette (10–12 puffs), and in the second, participants took 15
puffs with an EC containing 24-mg nicotine/mL e-liquid.
Changes to heart rate and BP were measured before and 10
min after each exposure. No statistically significant changes to
heart rate or BP were recorded after either exposure. All
parameters remained within normal ranges, other than systolic BP
after conventional cigarette exposure, which rose to the
prehypertensive range (~122 mmHg). However, baseline systolic
BP was borderline prehypertensive, and this change was not
significant. This was the only study identified that controlled for
sex by including only females in the study sample.
Two studies examined outcomes before and after acute
EC exposure in single groups without comparison groups
[51,54]. In the first (fair quality), 20 smokers (nine women)
participated in one session [51]. Individuals took 10 puffs
using ECs containing 18-mg nicotine/mL e-liquid. This
procedure was repeated five times at 30-min intervals. Heart
rate was measured every 20 s and averaged over 5 min. BP
was measured every 5 min. Heart rate rose statistically
significantly after the first two 10-puff bouts (from 67.5 bpm
at baseline to 75 bpm after the first 10-puff bout and ~ 72
bpm after the second), then fell for the remainder of the
session. No statistically significant changes to systolic or
diastolic BP were observed. Point estimates were not
reported. In the second study (poor quality), eight current
EC users (three women) provided their own products, which
ranged in nicotine content from 9 to 24-mg nicotine/mL
e-liquid [54]. Individuals took 10 puffs under observation,
then used ECs ad lib for 1 h, taking from 4 to 76 puffs. Mean
heart rate increased statistically significantly from baseline
within 5 min of participants' first puff (from 73.2 bpm to 78
bpm) and remained elevated throughout the session.
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4900 women) [61]. Investigators asked participants about past
and present smoking and EC use, perceived health benefits, side
effects, adverse events and changes to chronic health conditions
that they believed were related to EC use. No users reported
history of MI, stroke, VTE or PAD. Of those reporting
hypertension prior to initiating EC use (n=2365), 19 individuals
(0.8%) reported that their condition had worsened, 944 (39.9%)
reported that their condition had remained stable and 1149
(49.9%) reported that their condition improved. Of those
reporting coronary artery disease (CAD) (n= 318), seven
participants (2.2%) reported worsening of the condition, 116
(36.5%) reported that it remained stable and 171 (53.8%)
reported improvement. No results were reported by sex.
3.3. Research question #3
Our search for evidence on adverse outcomes associated
among women exposed to HC and nicotine from sources other
than cigarettes yielded 111 articles, 1 of which met inclusion
criteria [64] (Table 3). In this fair quality nonrandomized trial,
investigators exposed 46 female smokers and nonsmokers (some
taking COCs, some not) to a transdermal nicotine patch and a
placebo patch for 2.5 h with a 48-h washout period between
exposures. The authors divided participants into four groups:
smoking COC users, smoking non-COC users, nonsmoking
COC users and nonsmoking non-COC users. Smokers abstained
from cigarette use for 6 h prior to testing. Heart rate and BP were
measured after patch administration, and authors compared
cardiovascular parameters using a 2 (smoker/nonsmoker) × 2
(oral contraceptive [OC]/non-OC) × 2 (nicotine/placebo)
repeated measures analysis of variance. For all groups of
women, nicotine administration statistically significantly increased resting heart rate by a mean of 5.1 bpm (F [1.42]=5.7,
pb0.05). Authors observed statistically significant effects of
nicotine administration (pb0.05) and OC use (OC N non-OC,
pb0.001) on heart rate. Among smokers, COC users had a mean
heart rate of 69.1 bpm using the placebo and 77.7 bpm after
nicotine administration; among non-COC users, mean resting
heart rate was 72.5 bpm using placebo and 78.5 bpm after
nicotine administration. Among nonsmokers, COC users had a
mean heart rate of 72.6 bpm using the placebo and 73.8 bpm after
nicotine exposure, while non-COC users had a mean heart rate of
65.3 bpm using the placebo and 70 bpm after nicotine exposure.
No similar relationships were observed for BP.
3.4. Research question #4
Our searches for studies on adverse outcomes associated
with HC use among women also exposed to inhaled
propylene glycol or glycerin yielded 81 articles. None met
inclusion criteria for this review.

4. Discussion
3.2.3. Cross-sectional survey
We identified one poor quality cross-sectional Web-based
survey that recruited a global sample of EC users (n=19,411,

We found no direct evidence related to health effects of EC
use among HC users. Among studies of EC users in the general
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population, serious adverse cardiovascular events were rare.
Only one serious cardiovascular event (a case of MI) was
reported among a group of dual EC and cigarette users who
reported switching to ECs only during 12 months of
observation, with no further details about this case provided.
No instances of stroke, VTE or PAD were reported.
Eleven articles measured changes to heart rate after EC use. Of
these, seven found no significant increases to heart rate after EC
use compared with baseline, and four reported significant
changes; however, mean heart rate remained within the normal
range after EC exposures. In three articles, authors compared
changes to heart rate after EC exposure with changes after
conventional cigarette exposures; in two articles, the increase was
significantly greater with conventional cigarette exposure [50,54].
Of seven articles that recorded changes to BP after EC exposure,
two noted statistically significant increases to diastolic BP, with
postexposure diastolic BP remaining in the normal range in both
studies [50,53]; one article noted a statistically significant increase
to systolic BP after use of one of four EC products, with mean
systolic BP reaching the prehypertensive range [53]. In two
articles, authors tested for differences in changes to BP after
conventional cigarette versus EC exposure, with one study
finding a significantly greater increased difference in change to
diastolic BP after conventional cigarette use compared with one
EC model tested (but not others), and no differences between
groups in changes to systolic BP; the other found a significant
difference in changes to systolic (but not diastolic) BP after
conventional cigarette use compared with EC use [50,53].
One study found that acute exposure to both COC and
nicotine patch was associated with increases in heart rate, though
nicotine administration did not raise heart rate out of normal
ranges for either COC users or non-COC users. We found no
studies of propylene glycol or glycerin exposure among HC
users. While propylene glycol exposure has been associated
with eye and respiratory irritation, no evidence links exposure
with adverse cardiovascular outcomes [10,65], and ingestion is
generally considered safe [66]. Glycerin ingestion is also
generally recognized as safe [67], but heated glycerin can
produce acrolein, which may be associated with adverse
cardiovascular risk [13,68,69].
The findings of this review are generally consistent with a
recent narrative review that examined the connection between EC
use and cardiovascular risk [68] and included three of the studies
in this review, as well as evidence on NRT and the effect of ECs
on other biological markers (e.g., nicotine and cotinine levels and
pulmonary function). The authors of that paper concluded that EC
use was associated with a smaller risk of adverse cardiovascular
events than conventional cigarettes but that users should
nonetheless exercise caution because of the possibility of adverse
health effects, especially users who are at heightened risk of CVD.
The mechanisms through which conventional cigarette
smoking and CHC exposure lead to adverse cardiovascular
events are not fully understood; thus, it is difficult to determine
whether ECs are likely to lead to increased risk through the same
mechanisms. In the absence of direct evidence, it may be helpful
to consider the mechanisms through which cigarettes may lead

to cardiovascular harm and whether ECs are similar to
conventional cigarettes in these ways. Nicotine delivery may
be the most important similarity between the two products.
Nicotine is associated with adverse reproductive and cardiovascular outcomes [39,70]. However, nicotine does not appear to be
the component of cigarettes most strongly linked with major
adverse cardiovascular outcomes. Studies on the cardiovascular
risk associated with NRT products (e.g., nicotine patches, nasal
sprays and lozenges) and smokeless tobacco indicate that these
products do not appear to be associated with major cardiovascular events [71,72]. Exposure to products of combustion (e.g.,
carbon monoxide and oxidant gas) likely plays a larger role,
especially as a risk factor for thrombotic events [70,73].
The main limitation of this review is the lack of direct
evidence for our research question, with no studies identified
that examined EC use among women using HC. Thus, we
examined indirect evidence only, making it difficult to draw
conclusions about our primary research question.
There are shortcomings to the studies included in this review
as indirect evidence. The vast majority of this evidence
represents short-term findings related to cardiovascular markers
(i.e., heart rate, BP and cholesterol levels), with only two studies
following EC users for longer than 2 weeks [49,58] and only one
study reporting on clinical cardiovascular events [49]. The
relationship between changes to the intermediary markers
reported in these studies and risk of developing clinical CVD is
unclear. Thus, it is difficult to determine the clinical meaning of
this evidence or the effects of long-term EC use on
cardiovascular health.
Funding for the studies included in this review was provided by
industry, government and academia. Three studies were sponsored
by EC companies directly [53,56,59]. In a fourth, the EC test
products were provided by an EC company [57], and in a fifth,
authors reported having received previous funding from EC
companies [50]. One study was sponsored by an EC user advocate
group [61] and another by the Italian antismoking league [58]. The
remaining six studies were government or university sponsored
[51,52,54,55,60] or did not report funding [49].
Study quality ranged from fair to poor, with no good quality
studies. Only two of the studies on EC safety reported results by
sex [55,56], so we were not able to determine whether EC
exposure affected males and females differently. In six of the
studies, authors did not standardize EC dosage across the study
sample [49,54,57–60]; in three, no comparison group was
included [51,54,57]; and in one, neither exposures nor outcomes
were validated [61].
ECs were introduced into the United States recently (in
2009), which partially explains the paucity of safety data. In
order to answer our primary research question, additional
research is needed to examine incidence of adverse cardiovascular events associated with both EC and HC use. Given the
rarity of MI, stroke, VTE and PAD, especially among WRA,
case–control study design could be considered. Additional
prospective cohort studies should include a range of intermediary risk factors that are strongly associated with clinical
cardiovascular outcomes and be adequately powered to detect

Table 3
Nicotine and HCs.
Study design

Population
(including WRA)

Girdler, 1997
[64], US,
University of
California
Tobacco-Related
Disease Research
Program; NIH

Nonrandomized 76 individuals
trial
(n= 46 women).
Women separated
into four groups:
- Smoker/COC
users (n= 12).
- Smoker/nonCOC users (n=11).
- Nonsmoker/
COC users (n=12).
- Nonsmoker/
non-COC
users (n= 11).
All OC users
were using COCs
and had been
using COCs for
≥ 2 years.
Nonusers had not
taken COCs for
≥ 2 years.

Exposure(s)

Cardiovascular Results
outcome(s)

Nicotine condition: BP heart rate
Nicotine patch
applied for 2.5 h.
Placebo condition:
Placebo patch
applied for 2.5 h
48-h washout
period between
sessions.

For all groups of
women, significant
effects of nicotine
administration
(pb0.05) and COC
use (p≤0.001)
were observed for
heart rate.
Mean heart rate:
Smokers/OC usersAfter placebo, 69 bpm
After nicotine, 77.7 bpm
Smokers/non-COC users:
After placebo, 72.5 bpm
After nicotine, 78.5 bpm
Nonsmoker/OC users:
After placebo, 72.6 bpm
After nicotine, 73.8 bpm.
Nonsmoker/non-COC users:
After placebo, 65.3 bpm
After nicotine, 70 bpm.
No significant effects of
OC status or nicotine
exposure observed for
systolic or diastolic BP.

Strengths

Weaknesses

Grading of
quality⁎

Authors attempted
to standardize COC
exposure: All OC
users using COCs
for ≥ 2 years, and
75% of COC users
using low dose
estrogen/low dose
androgenic
progesterone COCs.
Nicotine exposure
standardized
(measures taken
2.5 h after patch
administration).
Comparison
condition (selfcomparisons under
placebo patch condition).
Authors reported
results by sex,
smoking status
and COC status.
Groups of women
(by smoking and
COC status) did
not differ in weight,
height, family
history of hypertension.

Authors reported II-2; Fair
acute effects only.
COC users were
significantly
younger than
nonusers.
Authors relied
on self-report
to exclude
individuals with
health problems.
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Author year, location, sources of
support

WRA, women of reproductive age.
⁎ USPSTF grading criteria used to assess study quality [48].
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changes in these markers. At least one clinical trial underway in
the United States aims to determine cardiovascular risk
associated with EC use and the relative contributions of nicotine
and other components of EC aerosol to this risk [74]. Finally, to
determine whether risk is further heightened among HC users,
investigators should include WRA, collect data on contraceptive
use and analyze outcomes by HC status.
Appendix A. Search strategies
Research question #1
((“Electronic cigarette" OR "E-cigarette" OR (Electronic
nicotine delivery system) OR “electronic nicotine delivery
device" OR (electrically heated cigarette) OR (electrically heated
smoking system))) AND (("Contraceptives, Oral, Combined"[Mesh] OR "Contraceptives, Oral"[Mesh] OR "Contraceptives,
Oral, hormonal"[Mesh] OR "Contraceptives, Oral, Combined"[Pharmacological Action] OR (contracept* AND (oral OR pill OR
tablet)) OR ((combined hormonal) OR (combined oral) AND
contracept*) OR (contracept* AND (ring OR patch)) OR "ortho
evra" OR NuvaRing) OR (progestin* OR progestins[MeSH] OR
Progesterone[MeSH] OR progesterone OR progestogen* OR
progestagen* OR "Levonorgestrel"[Mesh] OR Levonorgestrel
OR "Norgestrel"[Mesh] OR norgestrel OR etonogestrel AND
contracept*) OR dmpa OR "depot medroxyprogesterone" OR
"depo medroxyprogesterone" OR "depo provera" OR "net en"
OR "norethisterone enanthate" OR "norethindrone enanthate"
OR (contracept* AND (inject* OR implant)) OR ((levonorgestrel
OR etonogestrel) AND implant) OR implanon OR nexplanon
OR jadelle OR norplant OR uniplant OR sino-implant OR
(levonorgestrel-releasing two-rod implant) OR ("Intrauterine
Devices, Medicated"[Mesh] OR ((intrauterine OR intra-uterine)
AND (device OR system OR contracept*)) OR IUD OR IUCD
OR IUS OR mirena OR Skyla)).
Research question #2
“Electronic cigarette" OR "E-cigarette" OR (Electronic
nicotine delivery system) OR “electronic nicotine delivery
device" OR (electrically heated cigarette) OR (electrically
heated smoking system).

AND (oral OR pill OR tablet)) OR ((combined hormonal) OR
(combined oral) AND contracept*) OR (contracept* AND (ring
OR patch)) OR "ortho evra" OR NuvaRing) NOT ("Animals"[Mesh] NOT "Humans"[Mesh]) OR ((progestin* OR progestins[MeSH] OR Progesterone[MeSH] OR progesterone OR
progestogen* OR progestagen* OR “Levonorgestrel"[Mesh]
OR Levonorgestrel OR "Norgestrel"[Mesh] OR norgestrel OR
etonogestrel) AND contracept*) OR ((depo* AND medroxyprogesterone) OR dmpa OR (net en) OR (norethisterone
enant*) AND (contracept* OR inject* OR depo*)) OR (implant
AND contracept*) OR ((levonorgestrel OR etonogestrel) AND
implant) OR implanon OR nexplanon OR jadelle OR norplant
OR uniplant OR sino-implant OR (levonorgestrel-releasing
two-rod implant) OR ("Intrauterine Devices"[Mesh] OR
"Intrauterine Devices, Medicated"[Mesh] OR ((intrauterine
OR intra-uterine) AND (device OR system OR contracept*))
OR IUD OR IUC OR IUCD OR IUS OR mirena OR Skyla).
Research question #4
(("Propylene Glycol"[Mesh] OR "propylene glycol") OR
("Glycerol"[Mesh] OR glycerol OR glycerin OR glycerine OR
“glycerol-containing”)) AND ((("Contraceptives, Oral, Combined"[Mesh] OR "Contraceptives, Oral"[Mesh] OR "Contraceptives, Oral, hormonal"[Mesh] OR "Contraceptives, Oral,
Combined"[Pharmacological Action]) OR (contracept* AND
(oral OR pill OR tablet)) OR ((combined hormonal) OR
(combined oral) AND contracept*) OR (contracept* AND (ring
OR patch)) OR "ortho evra" OR NuvaRing) OR (progestin* OR
progestins[MeSH] OR Progesterone[MeSH] OR progesterone
OR progestogen* OR progestagen* OR "Levonorgestrel"[Mesh] OR Levonorgestrel OR "Norgestrel"[Mesh] OR norgestrel OR etonogestrel AND contracept*) OR dmpa OR "depo
medroxyprogesterone" OR "depo provera" OR "net en" OR
"norethisterone enanthate" OR "norethindrone enanthate" OR
(contracept* AND (inject* OR implant)) OR ((levonorgestrel
OR etonogestrel) AND implant) OR implanon OR nexplanon
OR jadelle OR norplant OR uniplant OR sino-implant OR
(levonorgestrel-releasing two-rod implant) OR ("Intrauterine
Devices, Medicated"[Mesh] OR ((intrauterine OR intra-uterine)
AND (device OR system OR contracept*)) OR IUD OR IUCD
OR IUS OR mirena OR Skyla).

Research question #3
("Nicotine"[Mesh] OR "Tobacco Use Disorder"[Mesh] OR
nicotine OR "Cotinine"[Mesh] OR "cotinine-N-oxide" [Supplementary Concept] OR "cotinine receptor" [Supplementary
Concept] OR "cotinine N-glucuronide" [Supplementary Concept] OR cotinine) OR "Tobacco, Smokeless"[Mesh] OR
“smokeless tobacco” OR "Tobacco Use Cessation Products"[Mesh] OR (nicotine replacement therapy) OR NRT OR
(Nicotine AND (patch OR inhaler OR gum) AND ((“Contraceptive agents, female”[MeSH] OR "Contraceptives, Oral,
Combined"[Mesh] OR "Contraceptives, Oral"[Mesh] OR
"Contraceptives, Oral, hormonal"[Mesh] OR "Contraceptives,
Oral, Combined"[Pharmacological Action]) OR (contracept*
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